JAK1 and myeloproliferative neoplasm: Consequently, JAK1/2 inhibitors like Ruxolitinib have proven effective at reducing the excess production of mature myeloid cells, inflammatory cytokine levels and the associated clinical symptoms in MPN, but have had limited efficacy in reducing the size of the MPN stem cell pool3.